Halozyme Therapeutics | HALO - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.87B 271M 2026-06
Baxter International USD 1.93B 118M 2026-06
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 5.59M 5.43M 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Intrexon USD 1.01M 344K 2024-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
MannKind USD 34.21M 5.38M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 4.09B 498M 2026-06
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
United Therapeutics USD 99.5M 33.9M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12